<SEC-DOCUMENT>0001178913-21-002984.txt : 20210913
<SEC-HEADER>0001178913-21-002984.hdr.sgml : 20210913
<ACCEPTANCE-DATETIME>20210913160555
ACCESSION NUMBER:		0001178913-21-002984
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20210913
DATE AS OF CHANGE:		20210913
EFFECTIVENESS DATE:		20210913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813676773
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-259489
		FILM NUMBER:		211249679

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>zk2126574.htm
<DESCRIPTION>S-8
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 7.5.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%2%%%-->
  <div>
    <div id="DSPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">As filed with the Securities and Exchange Commission on September 13, 2021</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;">Registration&#160;No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="line-height: 1.25;">&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div> <br>
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="line-height: 1.25;">&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM&#160;S-8</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">UNDER</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;">&#160;</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">Chemomab Therapeutics Ltd.</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Exact name of Registrant as specified in its charter)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" id="zc90b27b3620a401b9b581dc95588db16" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.5%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">State of Israel</div>
          </td>
          <td style="width: 1.03%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 48.48%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">81-3676773</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.5%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">(State or other jurisdiction of</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">incorporation or organization)</div>
          </td>
          <td style="width: 1.03%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 48.48%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">(I.R.S. Employer</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Identification Number)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.5%; vertical-align: middle;">&#160;</td>
          <td style="width: 49.5%; vertical-align: middle;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.5%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Atidim, Building 7</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Tel Aviv-Yafo, Israel</div>
          </td>
          <td style="width: 1.03%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 48.48%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">6158002</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.5%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Address of Principal Executive Offices)</div>
          </td>
          <td style="width: 1.03%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 48.48%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Zip Code)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Chemomab Ltd. 2015 Share Incentive Plan</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Full Title of the Plan)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Chemomab Therapeutics, Inc.<br>
      One Kendall Square<br>
      Building 1400E<br>
      Suite 14-105<br>
      Cambridge, MA 02139<br>
      (857) 259-4622</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div>
    <div style="line-height: 1.25;">&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">Copies to:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z30a2ab9a3cc64d7f80dcbc685f9805d4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 0.25%; vertical-align: top;">&#160;</td>
          <td style="width: 2.04%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 95.42%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">David S. Glatt</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ronen Bezalel<br>
              Jonathan M. Nathan<br>
              Meitar | Law Offices<br>
              16 Abba Hillel Rd.<br>
              Ramat Gan 5250608, Israel<br>
              +972 (3)&#160;610-3100</div>
          </td>
          <td style="width: 2.04%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.24%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <!--PROfilePageNumberReset%Num%2%%%-->
  <div><br>
    <div style="line-height: 1.25;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a&#160;non-accelerated&#160;filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large
      accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act of 1934, as amended.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z4bd4909f0dab4650b7df9799652a3c8a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 14%; vertical-align: middle;">&#160;</td>
          <td style="width: 70%; vertical-align: middle;">&#160;</td>
          <td style="width: 14%; vertical-align: middle;">&#160;</td>
          <td style="width: 2.46%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Large&#160;accelerated&#160;filer</div>
          </td>
          <td style="width: 70%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
          </td>
          <td style="width: 14%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Accelerated&#160;filer</div>
          </td>
          <td style="width: 2.46%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 14%; vertical-align: middle;">&#160;</td>
          <td style="width: 70%; vertical-align: middle;">&#160;</td>
          <td style="width: 14%; vertical-align: middle;">&#160;</td>
          <td style="width: 2.46%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Non-accelerated&#160;filer</div>
          </td>
          <td style="width: 70%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
          <td style="width: 14%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Smaller&#160;reporting&#160;company</div>
          </td>
          <td style="width: 2.46%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 14%; vertical-align: middle;">&#160;</td>
          <td style="width: 70%; vertical-align: middle;">&#160;</td>
          <td style="width: 14%; vertical-align: middle;">&#160;</td>
          <td style="width: 2.46%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 14%; vertical-align: bottom;">&#160;</td>
          <td style="width: 70%; vertical-align: bottom;">&#160;</td>
          <td style="width: 14%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Emerging&#160;growth&#160;company</div>
          </td>
          <td style="width: 2.46%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
      Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="line-height: 1.25;">&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CALCULATION OF REGISTRATION FEE</div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z5a03985787104e549605acbedfaf4188">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Title of Each Class&#160;of&#160;Securities<br>
              to be Registered</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amount</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">to be</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Registered(1)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Proposed</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Maximum</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Offering Price</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Per Share(2)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Proposed</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Maximum</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Aggregate<br>
              Offering Price(2)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amount of</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Registration Fee</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Ordinary shares, no par value per share, issuable upon exercise of options pursuant to the Chemomab Ltd. 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;) (3)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">12,903,660</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">0.74</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">9,548,709</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">1,042</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%;">
            <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Ordinary shares, no par value per share, reserved for issuance pursuant to the 2015 Plan (3)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">14,198,120</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.74</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">10,506,608</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">1,147</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Total</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">27,101,780</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">&#8212;</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">20,055,317</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">2,189</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <table cellspacing="0" cellpadding="0" id="zd5654115df744d98bb37a2457b8b3916" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 4.01%; vertical-align: top;">
              <div style="line-height: 1.25;">(1)</div>
            </td>
            <td style="width: 95.99%; vertical-align: top;" colspan="9">
              <div style="line-height: 1.25;">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this Registration Statement shall also cover any additional ordinary shares, no par value, of the Registrant
                (&#8220;Ordinary Shares&#8221;) that become issuable under the 2015 Plan, which was assumed by the Registrant in its merger with Chemomab Ltd. completed on March 16, 2021 (as discussed below) and under which equity awards have been converted into
                equity awards to receive the Registrant&#8217;s Ordinary Shares, based on the exchange ratio and as otherwise provided in the related Merger Agreement (as defined herein). Additionally, this Registration Statement shall also cover any additional
                Ordinary Shares that become issuable under the 2015 Plan by reason of any share dividend, share split, recapitalization or similar transaction effected without the Registrant&#8217;s receipt of consideration that would increase the number of
                outstanding Ordinary Shares. In addition, pursuant to Rule 416(c) under the Securities Act, this Registration Statement also covers an indeterminate amount of interests to be offered or sold pursuant to the employee benefits plan described
                herein.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: top;">
              <div style="line-height: 1.25;">(2)</div>
            </td>
            <td style="width: 95.99%; vertical-align: top;" colspan="9">
              <div style="line-height: 1.25;">Estimated solely for the purpose of calculating the registration fee in accordance with Rules 457(c) and Rule 457(h) of the Securities Act based on the average of the high and low prices of the Registrant&#8217;s
                American Depositary Shares (&#8220;ADSs&#8221;) as reported on the Nasdaq Capital Market on September 9, 2021 ($14.84), as adjusted to reflect the ratio of ADSs to Ordinary Shares described in footnote (3) below.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 4.01%; vertical-align: top;">
              <div style="line-height: 1.25;">(3)</div>
            </td>
            <td style="width: 95.99%; vertical-align: top;" colspan="9">
              <div style="line-height: 1.25;">These shares may be represented by ADSs, each of which currently represents twenty (20) Ordinary Shares. ADSs issuable upon deposit of the Ordinary Shares registered hereby have been registered under a separate
                registration statement on Form F-6 (File No. 333-192259).</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Proposed sale to take place as soon after the effective date of the</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">registration statement as awards under the plans are exercised and/or vest.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPLANATORY NOTE</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 28.35pt; line-height: 1.25;">Pursuant to the Agreement and Plan of Merger, dated December 14, 2020 (the &#8220;Merger Agreement&#8221;), by and among Anchiano Therapeutics Ltd. (&#8220;Anchiano&#8221; or the &#8220;Registrant&#8221;), CMB Acquisition Ltd., an
      Israeli limited company and wholly-owned subsidiary of Anchiano (&#8220;Merger Sub&#8221;), and Chemomab Ltd., an Israeli limited company (&#8220;Chemomab&#8221;), Merger&#160;Sub merged with and into Chemomab, with Chemomab surviving such merger as a wholly owned subsidiary of
      Anchiano, and Anchiano being renamed Chemomab Therapeutics Ltd. (the &#8220;Merger&#8221;). In accordance with the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), Registrant assumed the Chemomab Ltd. 2015 Share Incentive Plan (the
      &#8220;2015 Plan&#8221;), including all outstanding unexercised options to purchase Chemomab ordinary shares, no par value (&#8220;Chemomab ordinary shares&#8221;) and additional Chemomab ordinary shares reserved for issuance pursuant to the 2015 Plan. As a result, each
      such Chemomab ordinary share issuable under the 2015 Plan (including Chemomab ordinary shares underlying outstanding unexercised options) converted into ordinary shares, no par value, of the Registrant (&#8220;Ordinary Shares&#8221;) (which Ordinary Shares may
      be represented by ADSs) in accordance with the exchange ratio set forth in the Merger Agreement, with the number of Ordinary Shares of the Registrant subject to options and the exercise price of those options also being appropriately adjusted to
      reflect the exchange ratio set forth in the Merger Agreement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 28.35pt; line-height: 1.25;">The Registrant is filing this Registration Statement on Form S-8 to register an aggregate of 27,101,780 of the Registrant&#8217;s Ordinary Shares (including Ordinary Shares that may be represented by
      ADSs) issuable under the 2015 Plan, consisting of 12,903,660 Ordinary Shares underlying outstanding options and an additional 14,198,120 Ordinary Shares reserved for issuance pursuant to future awards.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PART I</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 35.45pt; line-height: 1.25;">The information called for by Items 1 and 2 of Part I of Form&#160;S-8&#160;is not being filed with or included in this Form&#160;S-8&#160;(by incorporation by reference or otherwise) in accordance with the rules and
      regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 35.45pt; line-height: 1.25;">The documents containing the information specified in Part I of Form S-8 will be sent or given to participants in the 2015 Plan as specified by Rule 428(b) under the Securities Act.&#160;Such documents
      and the documents incorporated by reference herein pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PART II</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 35.45pt; line-height: 1.25; font-style: italic;">In this Registration Statement, Chemomab Therapeutics Ltd. is sometimes referred to as &#8220;Registrant,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our.&#8221;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Item&#160;3. Incorporation of Documents by Reference.</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 35.45pt; line-height: 1.25;">The Registrant hereby incorporates by reference in this Registration Statement the following documents:</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z9440aa294ae24bcc962ab4c65ddc9df2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 1.65%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.34%; vertical-align: top;">
            <div style="line-height: 1.25;">(i)</div>
          </td>
          <td style="width: 95.01%; vertical-align: top;">
            <div style="line-height: 1.25;">the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 9, 2021 (the &#8220;Annual Report&#8221;);</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.65%; vertical-align: top;">&#160;</td>
          <td style="width: 3.34%; vertical-align: top;">&#160;</td>
          <td style="width: 95.01%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 1.65%; vertical-align: top;">&#160;</td>
          <td style="width: 3.34%; vertical-align: top;">
            <div style="line-height: 1.25;">(ii)</div>
          </td>
          <td style="width: 95.01%; vertical-align: top;">
            <div style="line-height: 1.25;">the Registrant&#8217;s Current Report on Form 8-K/A (File No. 001-38807) containing audited financial statements of Chemomab Ltd. as of, and for the year ended, December 31, 2020, filed with the SEC on March 19, 2021;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.65%; vertical-align: top;">&#160;</td>
          <td style="width: 3.34%; vertical-align: top;">&#160;</td>
          <td style="width: 95.01%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 1.65%; vertical-align: top;">&#160;</td>
          <td style="width: 3.34%; vertical-align: top;">
            <div style="line-height: 1.25;">(iii)</div>
          </td>
          <td style="width: 95.01%; vertical-align: top;">
            <div style="line-height: 1.25;">the description of the Ordinary Shares and ADSs contained in the Registrant&#8217;s registration statement on Form S-4, filed with the SEC on&#160;<a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883-1_s4.htm">January 13, 2021</a>, as may be further updated or amended in any amendment or report filed for such purpose; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.65%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.34%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 95.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.65%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.34%; vertical-align: top;">
            <div style="line-height: 1.25;">(iv)</div>
          </td>
          <td style="width: 95.01%; vertical-align: top;">
            <div style="line-height: 1.25;">all other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), since the end of the fiscal year covered by the Annual Report.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">3</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 28.35pt; line-height: 1.25;">All documents subsequently filed by the Registrant with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this
        Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part
        hereof from the date of filing of such documents.</div>
      <div style="text-indent: 28.35pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-indent: 28.35pt; line-height: 1.25;">For purposes of this Registration Statement, any document or any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or
        superseded to the extent that a subsequently filed document or a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated herein by reference modifies or supersedes such document or such
        statement in such document. Any such document or such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. </div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Item&#160;4. Description of Securities.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 35.45pt; line-height: 1.25;">Not applicable.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Item&#160;5. Interests of Named Experts and Counsel.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 35.45pt; line-height: 1.25;">None.</div>
    <br>
    <div style="line-height: 1.25; font-weight: bold;">Item&#160;6. Indemnification of Directors and Officers. </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">An Israeli company may indemnify an office holder in respect of certain liabilities either in advance of an event or following an event provided that a provision authorizing such indemnification is
      inserted in its articles of association. Our Articles of Association contain such a provision. An undertaking provided in advance by an Israeli company to indemnify an office holder with respect to a financial liability imposed on him or her in favor
      of another person pursuant to a judgment, settlement or arbitrator&#8217;s award approved by a court must be limited to events which in the opinion of the Board of Directors can be foreseen based on the company&#8217;s activities when the undertaking to
      indemnify is given, and to an amount or a criteria determined by the Board of Directors as reasonable under the circumstances, and such undertaking must detail the abovementioned events and amount or criteria.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In addition, a company may indemnify an office holder against the following liabilities incurred for acts performed as an office holder:</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zca2d1531d0cb428a99085270e9fe3586" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 1.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.5%; vertical-align: top;">
            <div style="margin-left: 17pt; line-height: 1.25;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder as a result of an investigation or proceeding instituted against him or her by an authority authorized
              to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability, such as a criminal penalty (as defined in the
              Companies Law), was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not
              require proof of criminal intent or in connection with a monetary sanction; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.5%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.5%; vertical-align: top;">
            <div style="margin-left: 17pt; line-height: 1.25;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or imposed by a court (i) in proceedings instituted against him or her by the company, on its behalf or
              by a third party, or (ii) in connection with criminal proceedings in which the office holder was acquitted, or (iii) as a result of a conviction for a crime that does not require proof of criminal intent.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">An Israeli company may insure a director or officer against the following liabilities incurred for acts performed as a director or officer:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zbfcba23aa3054b238dbb97efda5e6c14" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 1.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.5%; vertical-align: top;">
            <div style="margin-left: 17pt; line-height: 1.25;">a breach of duty of care to the company or to a third party, including a breach arising out of the negligent conduct of an office holder;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.5%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.5%; vertical-align: top;">
            <div style="line-height: 1.25; margin-left: 18pt;">a breach of duty of loyalty to the company, provided the director or officer acted in good faith and had a reasonable basis to believe that the act would not prejudice the interests of the
              company; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.5%; vertical-align: top;">
            <div style="margin-left: 24.1pt; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.17%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.5%; vertical-align: top;">
            <div style="line-height: 1.25; margin-left: 18pt;">financial liabilities imposed on the office holder for the benefit of a third party.</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">4</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">An Israeli company may not, however, indemnify or insure an office holder against any of the following:</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zfc27a817732e4178b653a212ab12f7f0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 1.06%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.61%; vertical-align: top;">
            <div style="margin-left: 24.8pt; line-height: 1.25;">a breach of duty of loyalty, except to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.06%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.61%; vertical-align: top;">
            <div style="margin-left: 24.8pt; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.06%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.61%; vertical-align: top;">
            <div style="margin-left: 24.8pt; line-height: 1.25;">a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.06%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.61%; vertical-align: top;">
            <div style="margin-left: 24.8pt; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.06%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.61%; vertical-align: top;">
            <div style="margin-left: 24.8pt; line-height: 1.25;">an act or omission committed with intent to derive unlawful personal benefit; or</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.06%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 97.61%; vertical-align: top;">
            <div style="margin-left: 24.8pt; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.06%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.33%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 97.61%; vertical-align: top;">
            <div style="margin-left: 24.8pt; line-height: 1.25;">a fine, monetary sanction, penalty or forfeit levied against the office holder.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Under the Israeli Companies Law, or the Companies Law, indemnification and insurance of office holders must be approved by our compensation committee, our Board of Directors and, in certain
      circumstances, by our shareholders. We have obtained directors&#8217; and officers&#8217; liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted
      by the Companies Law. In addition, we have entered into indemnification agreements with each of our directors providing them with indemnification for liabilities or expenses incurred as a result of acts performed by them in their capacity as our, or
      our subsidiaries&#8217;, directors and officers. This indemnification is limited both in terms of amount and coverage and it covers certain amounts regarding administrative proceedings insurable or indemnifiable under the Companies Law and our Articles of
      Association. In the opinion of the U.S. Securities and Exchange Commission, however, indemnification of directors and office holders for liabilities arising under the U.S. Securities Act of 1933, as amended, or the Securities Act, is against public
      policy and therefore unenforceable.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Item&#160;7. Exemption from Registration Claimed.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Not applicable.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Item&#160;8. Exhibits.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="zcf058bfa1a1b4ccf945131f07eadd017" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td nowrap="nowrap" style="width: 9.82%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Exhibit</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;">
            <div style="line-height: 1.25;">&#160;&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 88%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25; font-weight: bold;">Exhibit</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.82%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 9.82%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm">3.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;&#160;</div>
          </td>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm">Amended and Restated Articles of Association (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s current
                report on Form 8-K filed with the SEC on March 17, 2021)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.82%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 9.82%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;"><a href="exhibit_5-1.htm">5.1*</a></div>
          </td>
          <td style="width: 2%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;&#160;</div>
          </td>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">Opinion of Meitar | Law Offices</a></div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 9.82%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 9.82%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;"><a href="exhibit_23-1.htm">23.1*</a></div>
          </td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_23-1.htm">Consent of Somekh Chaikin, member firm of KPMG International, independent registered public
                accounting firm, for Chemomab Therapeutics Ltd. (formerly Anchiano Therapeutics Ltd.)</a></div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" rowspan="1" style="width: 9.82%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td rowspan="1" style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" rowspan="1" style="width: 9.82%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;"><a href="exhibit_23-2.htm">23.2*</a></div>
          </td>
          <td rowspan="1" style="width: 2%; vertical-align: bottom;"><br>
          </td>
          <td rowspan="1" style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_23-2.htm">Consent of Somekh Chaikin, member firm of KPMG International, independent registered public
                accounting firm, for Chemomab Ltd.</a></div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 9.82%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 9.82%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;"><a href="exhibit_5-1.htm">23.3*</a></div>
          </td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">Consent of Meitar | Law Offices (included in Exhibit 5.1)</a></div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 9.82%; vertical-align: top;">
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="text-align: center; line-height: 1.25;"><a href="#POWEROFATTORNEY">24.1*</a></div>
          </td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;"><a href="#POWEROFATTORNEY">Powers of Attorney (included on signature pages hereto)</a></div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 9.82%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm">99.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm">Chemomab Ltd. 2015 Share Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s
                registration statement on Form S-4 (SEC file number 333- 252070), filed with the SEC on January 13, 2021)</a></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3.78%; vertical-align: top;">
            <div style="line-height: 1.25;">*</div>
          </td>
          <td style="width: 96.22%; vertical-align: top;">
            <div style="line-height: 1.25;">Filed herewith.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Item&#160;9. Undertakings.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" border="0" id="z6a9da66e196f4faa80ae213e1b1e1a9a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 4%;">
              <div>
                <div>(a)</div>
              </div>
            </td>
            <td rowspan="1" style="width: 96%;">
              <div>
                <div>The Registrant hereby undertakes:</div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="z119fc116b37e4be6a8a75ae43f6ee336" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 4%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>
                <div>(1)</div>
              </div>
            </td>
            <td rowspan="1" style="width: 93%;">
              <div>
                <div>To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" id="z12ef21d061034ec39869af8dcea663a2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 4%;"><br>
              </td>
              <td style="width: 3%;"><br>
              </td>
              <td style="width: 3%;">
                <div>
                  <div>
                    <div>(i)</div>
                  </div>
                </div>
              </td>
              <td style="width: 90%;">
                <div>
                  <div>To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933;</div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">5</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <div style="text-align: justify; line-height: 1.25;">
        <div> <br>
          <div>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 4%;"><br>
                  </td>
                  <td style="width: 3%;"><br>
                  </td>
                  <td style="width: 3%; text-align: left; vertical-align: top;">
                    <div>
                      <div>
                        <div>
                          <div>(ii)</div>
                        </div>
                      </div>
                    </div>
                  </td>
                  <td style="width: 90%;">
                    <div>
                      <div>
                        <div>
                          <div>To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a
                            fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not
                            exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the
                            changes in volume and price represent no more than 20&#160;percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective Registration Statement; and</div>
                        </div>
                      </div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div><br>
          <div>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 4%;"><br>
                  </td>
                  <td style="width: 3%;"><br>
                  </td>
                  <td style="width: 3%;">
                    <div>
                      <div>
                        <div>
                          <div>(iii)</div>
                        </div>
                      </div>
                    </div>
                  </td>
                  <td style="width: 90%;">
                    <div>
                      <div>
                        <div>
                          <div>To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;</div>
                        </div>
                      </div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <br>
      </div>
    </div>
    <div style="line-height: 1.25;"><font style="font-style: italic;">provided, however</font>, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form&#160;S-8,&#160;and the information required to be included in a
      post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to section&#160;13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this Registration
      Statement.</div>
    <br>
    <div>
      <div>
        <div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 4%;">
                  <div>&#160;</div>
                </td>
                <td style="width: 3%; text-align: left; vertical-align: top;">
                  <div>
                    <div>(2)</div>
                  </div>
                </td>
                <td rowspan="1" style="width: 93%;">
                  <div>
                    <div>
                      <div style="line-height: 1.25;">
                        <div style="line-height: 1.25;">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
                          offered therein, and the offering of such securities at that time shall be deemed to be the initial&#160;<font style="font-style: italic;">bona fide&#160;</font>offering thereof.</div>
                      </div>
                    </div>
                  </div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
          <div><br>
          </div>
          <div>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 4%;">
                    <div>&#160;</div>
                  </td>
                  <td style="width: 3%;">
                    <div>
                      <div>(3)</div>
                    </div>
                  </td>
                  <td rowspan="1" style="width: 93%;">
                    <div>
                      <div>
                        <div style="line-height: 1.25;">
                          <div style="line-height: 1.25;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
                        </div>
                      </div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;"><br>
          </div>
        </div>
      </div>
    </div>
    <div style="line-height: 1.25;">(b)&#160;&#160;&#160;&#160;The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant&#8217;s annual report pursuant to Section&#160;13(a) or 15(d) of the Securities
      Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to
      be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">(c)&#160;&#160;&#160;&#160;Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or
      otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
      liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
      controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
      such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">6</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURES</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 35.45pt; line-height: 1.25;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
      Form&#160;S-8&#160;and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Tel Aviv, Israel, on this 13th day of September, 2021.</div>
    <div style="text-indent: 35.45pt; line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zdae53398794c456d9b0543489e89721d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.52%; vertical-align: middle;" colspan="1">&#160;</td>
          <td rowspan="1" style="vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
            <div style="line-height: 1.25; font-weight: bold;"> <br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.52%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="vertical-align: top; width: 4.02%;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 45.46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">/s/ Adi Mor</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.52%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="vertical-align: top; width: 4.02%;">
            <div style="line-height: 1.25;">Name:</div>
          </td>
          <td style="width: 45.46%; vertical-align: top;">
            <div style="line-height: 1.25;">Adi Mor</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.52%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="vertical-align: top; width: 4.02%;">
            <div style="line-height: 1.25;">Title:</div>
          </td>
          <td style="width: 45.46%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <br>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">POWER OF ATTORNEY<a name="POWEROFATTORNEY"><!--Anchor--></a></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 32.4pt; line-height: 1.25;">KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints Adi Mor and Sigal Fattal, jointly and severally, his or her
      true and lawful attorneys-in-fact and agents with full powers of substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all supplements amendments (including post-effective amendments) to this Registration
      Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and
      perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or
      their substitute or substitutes, may lawfully do or cause to be done by virtue thereof.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 32.4pt; line-height: 1.25;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z85ffe7781cfd407c80c1bc2ee5767a6d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">Signature</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Title</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Date</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 22.87%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 21.56%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic;"><u>/s/ Adi Mor</u></div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Executive Officer and Director (principal executive officer)</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;"> <br>
          </td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">September 13, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25;">Adi Mor</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 21.56%; vertical-align: top; text-align: center;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic;"><u>/s/ Sigal Fattal</u></div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Principal financial and accounting Officer</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">September 13,&#160; 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25;">Sigal Fattal</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 21.56%; vertical-align: top; text-align: center;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic;"><u>/s/ Stephen Squinto</u></div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Chairman of the Board of Directors</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">September 13,&#160; 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25;">Stephen Squinto</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 21.56%; vertical-align: top; text-align: center;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 21.56%; vertical-align: top; text-align: center;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic;"><u>/s/ Nissim Darvish</u></div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 50.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">September 13, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25;">Nissim Darvish</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top; text-align: center;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 21.56%; vertical-align: top; text-align: center;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic;"><u>/s/ Joel Maryles</u></div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">September 13, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25;">Joel Maryles</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top; text-align: center;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic;"><u>/s/ Alan Moses</u></div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Director&#160;</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">September 13, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25;">Alan Moses</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top; text-align: center;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic;"><u>/s/ Claude Nicaise</u></div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">September 13, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25;">Claude Nicaise</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 22.87%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 21.56%; vertical-align: top; text-align: center;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic;"><u>/s/ Neil Cohen</u></div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.56%; vertical-align: top;">
            <div style="line-height: 1.25; text-align: center;">September 13, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 22.87%; vertical-align: top;">
            <div style="line-height: 1.25;">Neil Cohen</div>
          </td>
          <td style="width: 2.72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.14%; vertical-align: top;">&#160;</td>
          <td style="width: 2.72%; vertical-align: top;">&#160;</td>
          <td style="width: 21.56%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">7</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">AUTHORIZED REPRESENTATIVE</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 35.45pt; line-height: 1.25;">Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Chemomab Therapeutics Ltd., has signed this
      registration statement on September 13, 2021.</div>
    <div style="text-indent: 35.45pt; line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.52%; vertical-align: middle;" colspan="1">&#160;</td>
          <td rowspan="1" style="vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS, INC.</div>
            <div style="line-height: 1.25; font-weight: bold;"> <br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.52%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="vertical-align: top; width: 4.02%;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 45.46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">/s/ Adi Mor</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.52%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="vertical-align: top; width: 4.02%;">
            <div style="line-height: 1.25;">Name:</div>
          </td>
          <td style="width: 45.46%; vertical-align: top;">
            <div style="line-height: 1.25;">Adi Mor</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.52%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="vertical-align: top; width: 4.02%;">
            <div style="line-height: 1.25;">Title:</div>
          </td>
          <td style="width: 45.46%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
  <div style="text-align: center;"><font id="DSPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">8</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>exhibit_5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 7.5.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div id="DSPFPageHeader">
      <div style="text-align: right; line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-weight: bold;"><u>Exhibit 5.1</u></font><br>
      </div>
      <div style="line-height: 1.25;"><br>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <img src="image00002.jpg"></div>
      <div style="text-align: right; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: right; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: right; line-height: 1.25;">September 13, 2021</div>
      <div style="text-align: right; line-height: 1.25;"> <br>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z02637722e00e4733b87a1221c63cb037" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: top;" colspan="3">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">Chemomab Therapeutics Ltd.</div>
              <div style="line-height: 1.25;">Kiryat Atidim, Building 7</div>
              <div style="line-height: 1.25;">Tel Aviv-Yafo, 6158002<br>
                <u>Israel</u></div>
            </div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25; font-size: 12pt;">
      <div style="text-align: center; margin-left: 24.5pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">RE:&#160;<u>Registration on Form&#160;S-8</u></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Ladies and Gentlemen:</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 24.5pt; line-height: 1.25;">We have acted as Israeli counsel to Chemomab Therapeutics Ltd., an Israeli company (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), in connection with its filing of a registration statement on Form&#160;S-8&#160;on or about September 13, 2021 (the &#8220;<font style="font-weight: bold;">Registration Statement</font>&#8221;), under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold;">Securities Act</font>&#8221;),
        relating to the registration of 27,101,780 of the Company&#8217;s ordinary shares, no par value (&#8220;<font style="font-weight: bold;">Ordinary</font>&#160;<font style="font-weight: bold;">Shares</font>&#8221;) (the &#8220;<font style="font-weight: bold;">Shares</font>&#8221;), including Shares that may be represented by American
        Depositary Shares (the &#8220;<font style="font-weight: bold;">ADSs</font>&#8221;), which may be issued under the Chemomab Ltd. 2015 Share Incentive Plan (the &#8220;<font style="font-weight: bold;">Plan</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 24.5pt; line-height: 1.25;">ADSs that represent the Shares will be issued under the Deposit Agreement, dated February 14, 2019, by and among the
        Company, the Bank of New York Mellon, as depositary (the &#8220;<font style="font-weight: bold;">Depositary</font>&#8221;), and the owners and holders from time to time of ADSs issued thereunder
        (the &#8220;<font style="font-weight: bold;">Deposit Agreement</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 24.5pt; line-height: 1.25;">In our capacity as counsel to the Company, we have examined originals or copies, certified or otherwise identified
        to our satisfaction, of the Company&#8217;s (i)&#160;Amended and Restated Articles of Association (the &#8220;<font style="font-weight: bold;">Articles</font>&#8221;), (ii) the Plan, (iii)&#160;resolutions of the
        Company&#8217;s board of directors and (iv)&#160;other statements of corporate officers and other representatives of the Company and other documents provided to us by the Company as we have deemed necessary or appropriate as a basis for this opinion. In such
        examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals and the conformity with the original documents of all documents submitted to us as
        copies or facsimiles. As to any facts material to this opinion, to the extent that we did not independently establish relevant facts, we have relied on certificates of public officials and certificates of officers or other representatives of the
        Company. We have also assumed the truth of all facts communicated to us by the Company and that all consents, minutes and protocols of meetings of the Company&#8217;s board of directors, which have been provided to us, are true and accurate and prepared
        in accordance with the Company&#8217;s Articles and all applicable laws. In addition, we have assumed that the Company will receive the full consideration for the Ordinary Shares (which may consist, in part or in full, of services performed for the
        Company).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 24.5pt; line-height: 1.25;">We are admitted to practice law in the State of Israel and the opinion expressed herein is expressly limited to the
        laws of the State of Israel.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 24.5pt; line-height: 1.25;">On the basis of the foregoing, we are of the opinion that the Shares being registered pursuant to the Registration
        Statement (including Shares represented by ADSs), when issued and paid for in accordance with the Plan, pursuant to agreements with respect to the Plan and, as the case may be, pursuant to the terms of the awards that have been or may be granted
        under the Plan, will be validly issued, fully paid and&#160;non-assessable.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 24.5pt; line-height: 1.25;">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this opinion
        and such consent, we do not admit that we are within the category of persons whose consent is required under Section&#160;7 of the Securities Act, the rules and regulations of the Securities and Exchange Commission promulgated thereunder or Item 509 of
        Regulation&#160;S-K&#160;promulgated under the Securities Act.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 24.5pt; line-height: 1.25;">This opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts,
        circumstances, events or developments that may be brought to our attention after the effective date of the Registration Statement that may alter, affect or modify the opinions expressed herein.</div>
      <div style="text-indent: 24.5pt; line-height: 1.25;"> <br>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="ze7ee8e47c0d24be9bdefb75edad9602d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;" colspan="1">&#160;</td>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25; font-style: italic;"><u>/s/ Meitar | Law Offices</u></div>
            </div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit_23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 7.5.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25; text-align: right;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">&#160;<u><font style="font-weight: bold;">Exhibit 23.1</font></u><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">The Board of Directors<br>
      Chemomab Therapeutics Ltd. (formerly Anchiano Therapeutics Ltd.):</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">We consent to the use of our report dated March 7, 2021, with respect to the consolidated financial statements of Anchiano Therapeutics
      Ltd. incorporated herein by reference.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zbc16592ddd504df0b7be82d795918b89" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: middle;">
            <div style="line-height: 1.25;"><u>/s/ Somekh chaikin</u></div>
            <div style="line-height: 1.25;">Somekh Chaikin</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: middle;">
            <div style="line-height: 1.25;">Certified Public Accountants (lsr.)</div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 100%; vertical-align: middle;">
            <div style="line-height: 1.25;">Member Firm of KPMG International</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Tel Aviv, Israel<br>
        <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">September 13, 2021</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>exhibit_23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 7.5.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 23.2</font></u><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">Consent of Independent Registered Public Accounting Firm</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="line-height: 1.25;">The Board of Directors<br>
        Chemomab Therapeutics Ltd. (formerly Anchiano Therapeutics Ltd.):</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">We consent to the use of our report dated March 16, 2021, with respect to the financial statements of Chemomab Ltd. incorporated herein by reference.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7d1b239c3c084da8af4bf2dd8dfe7a4e">

          <tr>
            <td style="width: 100%; vertical-align: middle;">
              <div style="line-height: 1.25;"><u>/s/ Somekh Chaikin</u></div>
              <div style="line-height: 1.25;">Somekh Chaikin</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: middle;">
              <div style="line-height: 1.25;">Certified Public Accountants (lsr.)</div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 100%; vertical-align: middle;">
              <div style="line-height: 1.25;">Member Firm of KPMG International</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Tel Aviv, Israel
        <div><br>
        </div>
        September 13, 2021</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !C ET# 2(  A$! Q$!_\0
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MM_\ @5)_C0!]DT5\;?\ "1>+O^@QK?\ X%2?XT?\)%XN_P"@QK?_ (%2?XT
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MCY@>XJMJ=RWBKX:7^NZU;6T>IV-[%!;WT4*Q&[5_O(0N Q7KG_Z] 'G5%%%
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M\OE>1P%V_>.<@XJS-IMRNJ:E,;&1D9)<2Q")FEWF+;@.<$KL;[W'3&<UUM%
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M_ 2/_"@9\6_:+?\ YX+_ -_31]HM_P#G@O\ W]-?:7_"-:%_T!=,_P# 2/\
MPH_X1K0O^@+IG_@)'_A0%SXM^T6__/!?^_IH^T6__/!?^_IK[2_X1K0O^@+I
MG_@)'_A1_P (UH7_ $!=,_\  2/_  H"Y\6_:+?_ )X+_P!_31]HM_\ G@O_
M ']-?:7_  C6A?\ 0%TS_P !(_\ "C_A&M"_Z NF?^ D?^% 7/BW[1;_ //!
M?^_IH^T6_P#SP7_OZ:^TO^$:T+_H"Z9_X"1_X4?\(UH7_0%TS_P$C_PH"Y\6
M_:+?_G@O_?TT?:+?_G@O_?TU]I?\(UH7_0%TS_P$C_PH_P"$:T+_ * NF?\
M@)'_ (4!<^+?M%O_ ,\%_P"_IH^T6_\ SP7_ +^FOM+_ (1K0O\ H"Z9_P"
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M5G&&:"%4+#T.!5R@14^SW7_/Z?\ OTM'V>Z_Y_3_ -^EJW10!4^SW7_/Z?\
MOTM'V>Z_Y_3_ -^EJW10!4^SW7_/Z?\ OTM'V>Z_Y_3_ -^EJW10!4^SW7_/
MZ?\ OTM'V>Z_Y_3_ -^EJW10!4^SW7_/Z?\ OTM'V>Z_Y_3_ -^EJW10!4^S
MW7_/Z?\ OTM'V>Z_Y_3_ -^EJW10!4^SW7_/Z?\ OTM'V>Z_Y_3_ -^EJW10
M!4^SW7_/Z?\ OTM'V>Z_Y_3_ -^EJW10!4^SW7_/Z?\ OTM'V>Z_Y_3_ -^E
MJW10!4^SW7_/Z?\ OTM'V>Z_Y_3_ -^EJW10!4^SW7_/Z?\ OTM'V>Z_Y_3_
M -^EJW10!4^SW7_/Z?\ OTM'V>Z_Y_3_ -^EJW10!4^SW7_/Z?\ OTM'V>Z_
MY_3_ -^EJW10!4^SW7_/Z?\ OTM'V>Z_Y_3_ -^EJW10!4^SW7_/Z?\ OTM'
MV>Z_Y_3_ -^EJW10!4^SW7_/Z?\ OTM'V>Z_Y_3_ -^EJW10!4^SW7_/Z?\
MOTM(EI)]IBFFN6D\L':NP <U<HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
